Literature DB >> 20716229

From NCE to NICE: the role of pharmacoeconomics.

Dyfrig A Hughes.   

Abstract

Mesh：

Year:  2010        PMID： 20716229      PMCID： PMC2949901          DOI： 10.1111/j.1365-2125.2010.03708.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  12 in total

1.  Cost-effectiveness analysis and efficient use of the pharmaceutical budget: the key role of clinical pharmacologists.

Authors:  Richard Edlin; Jeff Round; Claire Hulme; Christopher McCabe
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

2.  Pharmacoeconomics: NICE's approach to decision-making.

Authors:  Michael Rawlins; David Barnett; Andrew Stevens
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

3.  Money makes the world go round: the pervasiveness of pharmacoeconomics.

Authors:  J M Ritter
Journal:  Br J Clin Pharmacol       Date:  2008-12       Impact factor: 4.335

4.  Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada.

Authors:  Fiona M Clement; Anthony Harris; Jing Jing Li; Karen Yong; Karen M Lee; Braden J Manns
Journal:  JAMA       Date:  2009-10-07       Impact factor: 56.272

5.  New drugs for old: disinvestment and NICE.

Authors:  Dyfrig A Hughes; Robin E Ferner
Journal:  BMJ       Date:  2010-02-25

6.  Patient access schemes for high-cost cancer medicines.

Authors:  Steve Williamson
Journal:  Lancet Oncol       Date:  2010-02       Impact factor: 41.316

7.  Value based pricing, research and development, and patient access schemes. Will the United Kingdom get it right or wrong?

Authors:  Adrian Towse
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

Review 8.  Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis.

Authors:  Aaron S Kesselheim; Alexander S Misono; Joy L Lee; Margaret R Stedman; M Alan Brookhart; Niteesh K Choudhry; William H Shrank
Journal:  JAMA       Date:  2008-12-03       Impact factor: 56.272

9.  Effectiveness, safety and cost of drug substitution in hypertension.

Authors:  Atholl Johnston; Panagiotis Stafylas; George S Stergiou
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

10.  Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator.

Authors:  Mike Boggild; Jackie Palace; Pelham Barton; Yoav Ben-Shlomo; Thomas Bregenzer; Charles Dobson; Richard Gray
Journal:  BMJ       Date:  2009-12-02
View more
  7 in total

Review 1.  World health dilemmas: Orphan and rare diseases, orphan drugs and orphan patients.

Authors:  Christina N Kontoghiorghe; Nicholas Andreou; Katerina Constantinou; George J Kontoghiorghes
Journal:  World J Methodol       Date:  2014-09-26

2.  Pharmacoeconomics.

Authors:  Dyfrig A Hughes
Journal:  Br J Clin Pharmacol       Date:  2012-06       Impact factor: 4.335

3.  Mechanism-based approach to the economic evaluation of pharmaceuticals: pharmacokinetic/pharmacodynamic/pharmacoeconomic analysis of rituximab for follicular lymphoma.

Authors:  Joshua Pink; Steven Lane; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2012-05       Impact factor: 4.981

Review 4.  Role of the pharmacist in reducing healthcare costs: current insights.

Authors:  Kieran Dalton; Stephen Byrne
Journal:  Integr Pharm Res Pract       Date:  2017-01-25

5.  Impact of Clinical Pharmacist Intervention on Clinical Outcomes in the Critical Care Unit, Taif City, Saudi Arabia: A Retrospective Study.

Authors:  Abdullah Althomali; Ahmed Altowairqi; Afnan Alghamdi; Musim Alotaibi; Abdulrahman Althubaiti; Abdulaziz Alqurashi; Adnan Al Harbi; Majed Ahmed Algarni; Abdul Haseeb; Mohamed Hassan Elnaem; Faisal Alsenani; Mahmoud E Elrggal
Journal:  Pharmacy (Basel)       Date:  2022-08-31

6.  Overview of healthcare in the UK.

Authors:  Konstantina Grosios; Peter B Gahan; Jane Burbidge
Journal:  EPMA J       Date:  2010-10-25       Impact factor: 6.543

7.  Cost-outcome description of clinical pharmacist interventions in a university teaching hospital.

Authors:  James Gallagher; Stephen Byrne; Noel Woods; Deirdre Lynch; Suzanne McCarthy
Journal:  BMC Health Serv Res       Date:  2014-04-17       Impact factor: 2.655
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.